POLVERE, JACOPO
 Distribuzione geografica
Continente #
EU - Europa 558
NA - Nord America 182
AS - Asia 57
AF - Africa 9
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 811
Nazione #
IT - Italia 207
US - Stati Uniti d'America 176
IE - Irlanda 140
RU - Federazione Russa 62
FI - Finlandia 29
SE - Svezia 29
SG - Singapore 29
DE - Germania 22
FR - Francia 22
CN - Cina 17
GB - Regno Unito 12
CZ - Repubblica Ceca 11
CA - Canada 6
ES - Italia 6
NL - Olanda 6
ZA - Sudafrica 5
CI - Costa d'Avorio 4
PL - Polonia 3
BO - Bolivia 2
CH - Svizzera 2
IL - Israele 2
IR - Iran 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AT - Austria 1
EC - Ecuador 1
EU - Europa 1
GR - Grecia 1
HK - Hong Kong 1
IN - India 1
LT - Lituania 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
PT - Portogallo 1
RO - Romania 1
TH - Thailandia 1
TW - Taiwan 1
Totale 811
Città #
Dublin 139
Siena 60
Florence 36
Ashburn 32
Chandler 30
Helsinki 27
New York 26
Singapore 23
Shanghai 13
Princeton 11
Brno 9
Rome 9
Bacoli 6
Fremont 6
Málaga 6
Baronissi 5
Los Angeles 5
Manchester 5
Montreal 5
Munich 5
Washington 5
Abidjan 4
Agliana 4
Barolo 4
Figline Valdarno 4
Lanciano 4
Vanderbijlpark 4
Chicago 3
Fairfield 3
Gdynia 3
Messina 3
Naples 3
Salerno 3
Amsterdam 2
Bonn 2
Frankfurt am Main 2
Groningen 2
Lappeenranta 2
Lastra a Signa 2
London 2
Milan 2
Moscow 2
Nuremberg 2
Olomouc 2
Rogliano 2
Rosignano Marittimo 2
Southend 2
Trevi 2
Triggiano 2
Verona 2
Woodbridge 2
Arezzo 1
Athens 1
Auckland 1
Beijing 1
Bern 1
Boardman 1
Bologna 1
Boston 1
Central 1
Chiswick 1
Clifton 1
Colle di Val d'Elsa 1
Como 1
Friesland 1
Houston 1
Islamabad 1
Johannesburg 1
La Paz 1
Lisbon 1
Mumbai 1
Oslo 1
Ottawa 1
Parma 1
Poggibonsi 1
Quito 1
Sacramento 1
San Francisco 1
San Miniato Basso 1
Santa Clara 1
Sesto Fiorentino 1
Shenzhen 1
Sucre 1
The Hague 1
Tirana 1
Turin 1
Umeå 1
Vienna 1
Zanjan 1
Zurich 1
Totale 580
Nome #
B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV 88
Comparison of Immune Responses Elicited by BNT162b2, mRNA-1273 and ChAdOx1 COVID-19 Vaccines. 83
A third dose of mRNA-1273 vaccine improves SARS-CoV-2 immunity in HCT recipients with low antibody response after 2 doses 79
Antibody response in myelofibrosis patients after three doses of mRNA SARS-CoV-2 vaccine 78
Evidence of SARS-Cov-2-specific memory B cells six months after vaccination with BNT162b2 mRNA vaccine 69
The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients 64
Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine 57
The slower antibody response in myelofibrosis patients after two doses of MRNA sars-COV-2 vaccine calls for a third dose 57
B cell response six months after SARS-CoV-2 mRNA vaccination in people living with HIV under antiretroviral therapy 51
Characterization of the humoral and B-cell spike-specific immune response after mRNA SARS-CoV-2 vaccination in healthy and fragile subjects 45
Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine 44
Persistence of spike-specific memory B cells and antibodies nine months after two doses of BNT162b2 mRNA vaccine. 34
Third Sars-CoV-2 vaccine dose: B cell and antibody responses following heterologous and homologous vaccination strategies. 31
Antibody and B-cell responses in myelofibrosis patients after the third doses of mRNA SARS-CoV-2 vaccines 30
Longitudinal profiling of spike-specific antibody and B cell responses following mRNA-1273 SARS-CoV-2 vaccination in hematopoietic cell transplantation recipients 25
Spike-Specific memory B cell response in hematopoietic cell transplantation recipients following multiple mRNA-1273 vaccinations: a longitudinal observational study 24
Predicting humoral responses to primary and booster SARS-CoV-2 mRNA vaccination in people living with HIV: a machine learning approach 6
Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant 3
Totale 868
Categoria #
all - tutte 4.727
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.727


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202260 0 0 0 0 0 0 0 0 13 3 21 23
2022/2023242 14 23 37 16 15 26 14 22 12 11 43 9
2023/2024391 8 4 41 39 23 88 94 22 12 13 15 32
2024/2025175 46 24 96 9 0 0 0 0 0 0 0 0
Totale 868